Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-hepatic Oxaliplatin and Capecitabine for Breast Cancer Liver Metastases
NCT01387295Phase 2Completed
- Start
- Apr 2010
- Primary completion
- May 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in breast cancer. Primary endpoint: Response Rate up to 24 months. Started Apr 2010; status: completed.
02
Drugs
oxaliplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01387295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01387295.